Humanized antibodies with increased stability

Patent metadata

Field	Value
Publication number	US-12227569-B2
Application number	US-202117376314-A
Country	US
Kind code	B2
Filing date	Jul 15, 2021
Priority date	Mar 14, 2014
Publication date	Feb 18, 2025
Grant date	Feb 18, 2025

Abstract

The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

First claim

We claim:

1. An expression vector comprising a recombinant nucleic acid encoding:
a) a VH region comprising SEQ ID NO: 31;
b) a VL region comprising SEQ ID NO: 25;
c) a VL region comprising SEQ ID NO: 26;
d) a VH region comprising SEQ ID NO: 14;
e) a VL region comprising SEQ ID NO: 9; or
f) a VH region comprising SEQ ID NO: 15.

2. The expression vector according to claim 1 , wherein the expression vector comprises recombinant nucleic acids encoding an antibody or antibody fragment comprising SEQ ID NO: 14 and SEQ ID NO: 9.

3. The expression vector according to claim 1 , wherein the expression vector comprises recombinant nucleic acids encoding an antibody or antibody fragment comprising SEQ ID NO: 15 and SEQ ID NO: 9.

4. The expression vector according to claim 1 , wherein the expression vector comprises recombinant nucleic acids encoding an antibody or antibody fragment comprising SEQ ID NO: 31 and SEQ ID NO: 25.

5. The expression vector according to claim 1 , wherein the expression vector comprises recombinant nucleic acids encoding an antibody or antibody fragment comprising SEQ ID NO: 31 and SEQ ID NO: 26.

6. A host cell comprising an expression vector according to claim 1 .

7. A pair of expression vectors, wherein said pair of expression vectors comprises:
a) a first expression vector comprising a recombinant nucleic acid encoding an antibody or antibody fragment VH region comprising SEQ ID NO: 31 and a second expression vector comprising a recombinant nucleic acid encoding an antibody or antibody fragment VL region comprising SEQ ID NO: 25;
b) a first expression vector comprising a recombinant nucleic acid encoding an antibody or antibody fragment VH region comprising SEQ ID NO: 31 and a second expression vector comprising a recombinant nucleic acid encoding an antibody or antibody fragment VL region comprising SEQ ID NO: 26;
c) a first expression vector comprising a recombinant nucleic acid encoding an antibody or antibody fragment VH region comprising SEQ ID NO: 14 and a second expression vector comprising a recombinant nucleic acid encoding an antibody or antibody fragment VL region comprising SEQ ID NO: 9; or
d) a first expression vector comprising a recombinant nucleic acid encoding an antibody or antibody fragment VH region comprising SEQ ID NO: 15 and a second expression vector comprising a recombinant nucleic acid encoding an antibody or antibody fragment VL region comprising SEQ ID NO: 9.

8. A host cell comprising a pair of expression vectors according to claim 7 .

9. A method of producing an antibody or antibody fragment that binds to a KIR3DL2 polypeptide, the method comprising culturing host cells of claim 8 and recovering the antibody or antibody fragment from the host cell culture.

10. The method according to claim 9 , wherein said host cells express an antibody or antibody fragment comprising an antibody or antibody fragment VH region comprising SEQ ID NO: 31 and an antibody or antibody fragment VL region comprising SEQ ID NO: 25.

11. The method according to claim 9 , wherein said host cells express an antibody or antibody fragment VH region comprising SEQ ID NO: 31 and an antibody or antibody fragment VL region comprising SEQ ID NO: 26.

12. The method according to claim 9 , wherein said host cells express an antibody or antibody fragment VH region comprising SEQ ID NO: 14 and an antibody or antibody fragment VL region comprising SEQ ID NO: 9.

13. The method according to claim 9 , wherein said host cells express an antibody or antibody fragment VH region comprising SEQ ID NO: 15 and an antibody or antibody fragment VL region comprising SEQ ID NO: 9.

14. The method according to claim 9 , wherein said host cells are Chinese Hamster Ovary (CHO) cells.

Assignees

• Innate Pharma

Inventors

• Gauthier Laurent
• Schneider Nicolas

Classifications

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title